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OBJECTIVES: Expert consensus recommends calendar based in-office follow-up
(FU) for pacemakers (PM) twice annually, for internal cardioverter defibrillator (ICD)
or cardiac resynchronisation therapy devices (CRT) four times a year. To estimate
the societal costs of these FUs in Germany and the UK (UK). To estimate potential
cost savings from switching from conventional to a BIOTRONIK Home Monitoring
FU (remote monitoring) regimen. METHODS: Prevalence-based estimates on the
number of in-office FU visits were combined with data on private and ambulance
transport and hospital services, with costs projected until 2015. RESULTS: Annual
cost of routine FU in Germany are estimated to climb from EURO 106 mio (2010) to
142 mio (2015). For the UK, costs are forecast to rapidly increase from EURO 31 mio
(2010) to 49 mio (2015). In Germany, patients bear the majority of the costs (61%),
followed by hospital service costs (31%). In the UK, the situation is reversed with
hospital costs contributing the most (84%), followed by patient travel costs (12%).
The remainder is health insurance costs for ambulance transport. If 50% of all
patients would attend one in-office visit annually and have their other FUs per-
formed with Home Monitoring, annual cost savings in 2015 could reach EURO 43.9
mio in Germany, and EURO 14.7 mio in the UK. CONCLUSIONS: For the first time,
costs of FU for PM and ICD/CRT in Germany and the UK are presented. As modern
devices are capable to self-declare parameter deviations indicative for malfunc-
tions or worsening disease, remote monitoring can help eliminating unnecessary
visits. The presented savings are expected to be heavily underestimated due to not
considering the impact of earlier event detection and improved disease outcomes.
Savings could be invested in remote monitoring technologies, and freed medical
specialist capacities be re-directed to CIED patients in real need of FU visits.
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OBJECTIVES: In the US the monitoring of patients with Chronic Myeloid Leukaemia
(CML) presents extensive intra- and inter-lab variability, thus a standardised, au-
tomated test should allow for improvement in patient management and health
outcomes. The aim of the study was to estimate the budget impact and improved
testing accuracy associated with a the use of a standardised, automated BCR-ABL
monitoring test (SBAT) when compared to laboratory developed tests (LDTs) for
newly diagnosed CML patients over a 5-year period in the US.METHODS: Epidemi-
ology data regarding the incidence of Philadelphia positive (Ph) CML patients who
would be treated with a tyrosine kinase inhibitor (TKI) were combined with work-
flow cost and accuracy (sensitivity and specificity) data associated with the se-
quential testing and monitoring of newly diagnosed CML patients. A survey of US
laboratories was conducted to determine the labour and materials costs associated
with the SBAT versus LDTs. A testing algorithm based on NCCN guidelines was
used to capture a number of different tests including testing for major molecular
response (SBAT versus LDTs), complete cytogenetic response (routine and FISH-
fluorescence in situ hybridisation), and mutation analysis. RESULTS: Results indi-
cate that the SBAT is both less resource- and labour- intensive, and can be carried
out at a cost that is lower than when an LDT is used. In addition, overall test
accuracy increases when the SBAT is used instead of an LDT. For example, for every
100 patients who follow BCR-ABL monitoring according to NCCN guidelines, sav-
ings of approximately $386,180 and approximately 327 more accurate test results
could be achieved over 5 years. CONCLUSIONS: The benefits from a SBAT when
compared to LDTs are not only from the reduction of intra- and inter-lab variability
(increased accuracy) but also in economic terms due to lower overall costs. There-
fore, a SBAT represents a cost-saving alternative versus LDTs.
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OBJECTIVES: The aim of this paper is to illustrate a methodology to develop a BIA,
assisting the decision maker in answering the question on financial sustainability.
METHODS:The analysis compared the new coated urethral catheter (alternative A)
to the long-term catheter currently in use in the region (alternative B). The study,
built on efficacy data including “asymptomatic bacteriuria” solely, adopted the
perspective of the Regional Health Service. A survey was conducted in seven local
health authorities (LHAs) within the Region to obtain consumption data and the
average price of respectively the new and currently used long-term catheters. The
estimate of regional consumption of alternative B was obtained by projecting the
consumption of 7 LHAs on the basis of the percentage of total inpatient admissions.
The analysis included technology costs and the costs of additional hospitalization
days due to Catheter Associated Urinary Tract Infections (CAUTI). Sensitivity anal-
yses were conducted to test the robustness of the results in the “base case”.
RESULTS: In 2010 approximately 25.000 long-term catheters with an average price
of 3.57 € were consumed. The regional estimate of annual consumption is about
221.560 catheters, with a total cost of € 791.000 per year. In the case of adopting
alternative A, the base case analysis estimated savings of around € 200.000 per year.
The one-way sensitivity analysis confirmed the extreme variability of the final
result as a function of the confidence interval of the clinical efficacy. A more favor-
able result for the new catheter can be reached using a “two-way” analysis, com-
bining a higher CAUTI incidence and a higher level of effectiveness (€2.045.866).
CONCLUSIONS: The results are strongly influenced by the effectiveness of the new
technology: a slight clinical benefit is enough to make the new catheter economi-
cally viable.
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OBJECTIVES:Open spine surgery (OS) is associated with significant muscle trauma
leading to delayed recovery, prolonged pain, and significant medical resource uti-
lization. Minimal Access Spinal Technologies (MAST™) aim at minimizing muscle
trauma, reduce blood loss, decrease postoperative pain, reduce length of stay in
hospital (LoS), and expedite return to normal activities for the patient. The objec-
tive of this study is to determine and compare the resource consumption associ-
ated with open vs. minimal invasive surgery in patients with degenerative spinal
disorder. METHODS: This activity-based cost-analysis was conducted in two Ital-
ian hospitals where patient flow and resource utilization were mapped and seg-
mented through interviews with medical staff. Unit costs were retrieved from pub-
lic sources and hospital data for the following categories 1) staff time; 2) tests; 3)
drugs/consumables; 4) operating room (OR); 5) spinal implants/instrumentation;
and 6) general costs. Costs were compared between pathways (open vs. MAST™)
and for each phase (pre-hospitalization, hospitalization, surgery, post-surgery and
follow-up. RESULTS: Both surgery and post-surgery were the most resource in-
tense episodes: on average post-surgery accounted for 14% of the total costs in
MAST™, and 24% in OS. MAST™ was associated with less overall resource use in
both hospitals, mainly driven by shorter LoS post surgery (2 vs. 4 days), less blood
loss and less demanding wound care. Total hospitalization costs were €6970-8310
for MAST™ and €8021- 8760 for OS. CONCLUSIONS: The study confirms published
evidence on the shorter LoS with MAST™ and the economic benefits of a less
invasive procedure. Despite initial higher investments (instrumentation, learning
curve) MAST™ may be an effective and cost-saving alternative to OS. Further cost
savings may be incurred due to faster return to work, not investigated in this study.
PMD19
COST-EFFECTIVENESS OF IMPLANTABLE DEFIBRILLATORS AFTER
MYOCARDIAL INFARCTION BASED ON 8-YEAR FOLLOW-UP DATA (MADIT II)
Gandjour A1, Holler A2, Adarkwah CC3
1Pennington Biomedical Research Center/Louisiana State University, Baton Rouge, LA, USA,
2University of Cologne, Köln, Germany, 3Maastricht University, Maastricht, The Netherlands
OBJECTIVES: About 190,000 Germans suffer a myocardial infarction (MI) each year.
Of these, 25% may be eligible for an implantable cardioverter defibrillator (ICD) due
to low left ventricular ejection fraction. Given the high costs of implantation, the
purpose of this study was to assess the cost-effectiveness of ICDs compared to
conventional therapy in patients with an ejection fraction  30% after MI in
Germany. METHODS: The economic evaluation was performed from the perspec-
tive of the German statutory health insurance (SHI). In order to simulate costs and
effectiveness over lifetime, a Markov model was constructed with 7 health states.
The model was based on 8-year follow-up data for ICD implantation after MI (MA-
DIT II), which were published recently. RESULTS: The analysis shows that ICD
implantation compared to conventional therapy in patients fulfilling MADIT-II cri-
teria has a cost-effectiveness ratio of €44 736 per quality-adjusted life year gained.
If every patient insured by the SHI and fulfilling the MADIT-II criteria would receive
an ICD, the model suggests expenditures between €173 million and €1.7 billion per
year.CONCLUSIONS: ICD therapy cannot be considered clearly cost-effective when
compared to many well-accepted interventions. If policy makers decide to reim-
burse ICDs in the MADIT-II population, they will need to either raise premiums or
abandon coverage for other currently funded medical interventions.
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OBJECTIVES: Deep brain stimulation (DBS) use in dystonia is associated with high
energy needs and as such frequent replacement of the device. The first recharge-
able DBS device (Activa
®
RC) offers a guaranteed 9 years longevity. Our objective is
to perform a cost analysis of Activa
®
RC compared to the non rechargeable neuro-
stimulators in dystonia patients in France. METHODS: A retrospective data collec-
tion was performed in a Neurosurgery Department (Pr. Ph. Coubes - Montpellier
Public Hospital) with significant experience in DBS for dystonia. The cost analysis
was based on direct medical costs, from a national insurance perspective. The
evaluation concerns the device and hospitalization tariffs, the procedure cost being
included in the hospitalization tariffs, in France, for the public hospitals. We com-
pared the time to replacement with non-rechargeable devices versus rechargeable
device, extrapolated over 9 years. A sensitivity analysis was performed using time-
to-replacement variable. RESULTS: The cohort included 63 consecutive dystonia
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